A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.23.16_SUPPL.3151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Epithelial ovarian cancer: focus on targeted therapy.

  2011cites this paper
• Novel therapies in gynaecological cancer

  2011cites this paper
• New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.

  2008cites this paper
• Developments in Epidermal Growth Factor Receptor-Targeting Therapy for Solid Tumors: Focus on Matuzumab (EMD 72000)

  2008cites this paper
• Molecular Targeted Therapies in the Treatment of Ovarian Cancer

  2007cites this paper
• Inhibitors of signal transduction protein kinases as targets for cancer therapy.

  2006cites this paper
• New targets and non-cytotoxics in ovarian cancer.

  2006cites this paper
• Biological agents versus chemotherapy in the treatment of colorectal cancer

  2006cites this paper
• Investigational agents for epithelial ovarian cancer

  2005cites this paper